Diagnostic performance of increased prolidase activity in schizophrenia

Basit Öğe Kaydı
dc.contributor.authorGunes, Mehmet
dc.contributor.authorBulut, Mahmut
dc.contributor.authorDemir, Suleyman
dc.contributor.authorIbiloglu, Aslihan Okan
dc.contributor.authorKaya, Mehmet Cemal
dc.contributor.authorAtli, Abdullah
dc.contributor.authorKaplan, Ibrahim
dc.date.accessioned2024-04-24T16:15:44Z
dc.date.available2024-04-24T16:15:44Z
dc.date.issued2016
dc.departmentDicle Üniversitesien_US
dc.description.abstractWe investigated whether prolidase activity has a diagnostic test value in schizophrenia and assessed the relation between prolidase activity and sociodemographic-clinical characteristics of patients with schizophrenia. Fifty patients with schizophrenia (diagnosed as schizophrenia according to DSM-V criteria) and 50 healthy volunteers were included in this study. Case and control groups had a similar distribution in age, sex, body mass index (BMI), and smoking status. Serum prolidase activity was measured in both groups and was determined to be significantly higher in the patient group (509.706 +/- 41.918) compared to the control group (335.4 +/- 13.6; t = 6.231; p = 0.0001). A cut-off point of 392.65 U/L prolidase was determined for diagnostic measures from the plotted ROC curve. The area under the ROC curve was 1.000, which was significant (p < 0.0001). Higher values were assigned as the disease state. Both positive predictive value (PPV) and negative predictive value (NPV) were 100% at the cut-off point of 392.650 U/L. The prolidase levels of the control group were all below the cut-off point. There were no statistically significant differences between the two groups with regard to age, gender, or BMI (p > 0.05), and no correlation was found between mean prolidase activity and age of onset of the disease, family history, disease duration, number of hospitalizations, subtypes of schizophrenia, PANSS scores or sub scores, CGI-S scores, S-A scale scores, and the antipsychotic treatment (p > 0.05). The results of this study indicate that serum prolidase activity may be a useful diagnostic test for schizophrenia; however, further studies are needed to verify this. (C) 2015 Elsevier Ireland Ltd. All rights reserved.en_US
dc.identifier.doi10.1016/j.neulet.2015.12.036
dc.identifier.endpage40en_US
dc.identifier.issn0304-3940
dc.identifier.issn1872-7972
dc.identifier.pmid26724223
dc.identifier.scopus2-s2.0-84952802894
dc.identifier.scopusqualityQ2
dc.identifier.startpage36en_US
dc.identifier.urihttps://doi.org/10.1016/j.neulet.2015.12.036
dc.identifier.urihttps://hdl.handle.net/11468/15907
dc.identifier.volume613en_US
dc.identifier.wosWOS:000369463200007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherElsevier Ireland Ltden_US
dc.relation.ispartofNeuroscience Letters
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectProlidase Activityen_US
dc.subjectDiagnostic Performanceen_US
dc.subjectBiochemical Markeren_US
dc.subjectSchizophreniaen_US
dc.titleDiagnostic performance of increased prolidase activity in schizophreniaen_US
dc.titleDiagnostic performance of increased prolidase activity in schizophrenia
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu